Basic Info

4025 Sorrento Valley Boulevard
San Diego, CA 92121
(858) 678-0800
  N/A
www.lpath.com
Preferred contact:
  Scott Pancoast - President/CEO
Lpath Inc
Business Identifier: Monoclonal antibodies for the neutralization of bioactive lipids
Public Profile:
Lpath Inc, a subsidiary of Neighborhood Connections Inc and formally doing business as Medlyte Inc & Lpath Therapeutics Inc, is a biomedical company focused on the research and development of monoclonal antibodies that can target and neutralize bioactive lipids. Lipidomics, the study of lipids, is an emerging field of research that has identified dozens of bioactive lipids that contribute to disease. Once a disease-causing lipid is identified, the next step, generating a compound that neutralizes the relevant bioactive lipid, has proven difficult. Lpath has developed a platform technology, ImmuneY2, to generate monoclonal antibody drug candidates for two well-validated two bioactive lipid targets: S1P and LPA. The company is currently applying the ImmuneY2 technology to other bioactive lipid targets that are involved in important disease processes, such as inflammation, cancer, pain, asthma and sepsis.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year 2004 Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol OTC : LPTN
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Development Of Therapeutic Monoclonal Antibody To The Bioactive Lipid Lysophospha
Structure Based Design Of Humanized Monoclonal Antibodies That Recognize Bioactiv
Sphingomab Mitigates the Multiple Pathologies of Age-Related Macular Degeneration
Commercialization of ASONEP for the Treatment of Cancer

      

Media coverage